Newsroom | 4806 results

IRVINE, Calif.--(BUSINESS WIRE)--Nihon Kohden, a global leader in neurodiagnostic technology, will showcase its integrated EEG portfolio at the American Epilepsy Society (AES) 2025 Annual Meeting, held December 5–9 in Atlanta. Attendees are invited to Booth #725 to explore solutions shaped through extensive collaboration with the clinicians who use them—bringing together mobility, connectivity and performance to advance neurological care. With a history of advancing EEG technology that predates...

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 4,860 shares of the Company’s common stock to two new employees (the “Inducement Grants”) on December 2, 2025 (the “Grant Date”). The Induce...

DUBLIN--(BUSINESS WIRE)--The "Exosome Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, 2020-2030" has been added to ResearchAndMarkets.com's offering. The Global Exosome Therapeutics Market, valued at USD 32.63 Million in 2024, is projected to experience a CAGR of 41.56% to reach USD 262.58 Million by 2030. The market's expansion is fundamentally supported by an escalating understanding of exosome biology, the increasing prevalence of chronic and age-relat...

MINNEAPOLIS--(BUSINESS WIRE)--Dietitian Live, a pioneering healthcare start-up that merges medical nutrition therapy with subconscious rewiring to reverse chronic disease, today announced a healthcare breakthrough showing that the human brain is the primary driver of healing in chronic metabolic disease. Through its patent-pending Quantum Mind Architecture™ program, the company has demonstrated that when subconscious beliefs are rewired from fear to love, the body’s biology naturally realigns w...

SEOUL, South Korea--(BUSINESS WIRE)--Famenity's BF-7® gains global attention as a cognitive-health ingredient backed by more than 12 human studies and major regulatory approvals....

CAMBRIDGE, Mass. & SINGAPORE--(BUSINESS WIRE)--Sunbird Bio, a biotechnology company developing proprietary blood-based technologies to improve diagnosis and treatment of neurological disorders, announced new data demonstrating that the company’s blood-based sunbird αSyn™ assay accurately detected the aggregation of extracellular vesicle (EV)-bound alpha-synuclein (α-synuclein) in the brain from a simple blood draw. Results from the study were shared in an oral presentation at the Clinical Trial...

GREENVILLE, N.C. & CHICAGO--(BUSINESS WIRE)--ECU Health, a rural health system serving 29 counties in eastern North Carolina, has partnered with Artisight to introduce Smart Hospital technology across its facilities, starting with five hospitals and expanding to more in the coming year. This new platform will make telehealth services more efficient by expanding specialized care from ECU Health Medical Center to patients in ECU Health hospitals across eastern North Carolina and improve the exper...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that the company will present and participate in the Sachs Associates 9th Annual Neuroscience Innovation Forum on January 11, 2026 during “J.P. Morgan Week 2026” in San Francisco. Additionally, Enveric will attend Biotech Showcase 2026, which is b...

BOSTON--(BUSINESS WIRE)--Seaport Therapeutics to present at 2025 RBC Capital Markets Healthcare Private Company Conference and participate in one-on-one meetings....

TOKYO--(BUSINESS WIRE)--Meiji Seika Pharma Co., Ltd. (ufficio centrale: Chuo-ku, Tokyo, Presidente: Toshiaki Nagasato) ha annunciato oggi un investimento in partecipazioni strategiche in Lyric Bio, Inc. (ufficio centrale: San Carlos, USA, fondato dal CEO: Kayj Shannon e dalla Chief Scientific Officer Melanie Matheu). Grazie a questo investimento, Meiji Seika Pharma desidera accelerare lo sviluppo di fase iniziale dell'innovativa piattaforma di Lyric Bio per la produzione di immoglobulina umana...